Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders
Authors' conclusion
Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time.
Study context
- Population
- Patients with rheumatoid arthritis (RA) who developed lymphoproliferative disorder (LPDs) and visited 53 hospitals in Japan between January 1999 and March 2021
- Participants
- 770 vs 752
- Exposure
- RA-associated LPD vs sporadic LPD; RA-associated LPD (RA-LPD) by antirheumatic drugs administered
- Sporadic LPDn = 770reference
- RA-LPDn = 752
- Outcome
- Clinicopathologic features of LPD
Methodological detailsmulticenter, 53 hospitals in Japan
- Multicenter
- 53 hospitals in Japan
Main finding
As reported in the abstract
Clinicopathologic features
- Significant differences in clinicopathologic features between RA-LPD and sporadic LPD
- High frequency of LPD-associated immunosuppressive conditions on histopathology
- Methotrexate (MTX) plus tacrolimus and MTX plus tumor necrosis factor inhibitor (TNFi) groups had different affected site frequencies and histologic subtypes than MTX-only group
- MTX and TNFi may synergistically affect susceptibility to Epstein-Barr virus infection
Observational data: associations, not effects.
Further findings
Regrowth after spontaneous regression, by antirheumatic drugs after LPD onset
- Tocilizumab-only therapy associated with lower frequency of regrowth than other regimens
Original publication
Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders. Arthritis Rheumatol. Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →